Cited by 483RNA Interference and Gene DeliveryExtracellular vesicles in diseaseNanoparticle-Based Drug Delivery

Exosome-mediated delivery of hydrophobically modified siRNA for huntingtin mRNA silencing

Open access
Didiot, Marie-Cécile, Hall, Lauren M, Coles, Andrew H, Haraszti, Reka A, Godinho, Bruno MDC, Chase, Kathryn, Sapp, Ellen, Ly, Socheata +8 more·2016·Molecular Therapy

Abstract

Delivery represents a significant barrier to the clinical advancement of oligonucleotide therapeutics for the treatment of neurological disorders, such as Huntington's disease. Small, endogenous vesicles known as exosomes have the potential to act as oligonucleotide delivery vehicles, but robust and scalable methods for loading RNA therapeutic cargo into exosomes are lacking. Here, we show that hydrophobically modified small interfering RNAs (hsiRNAs) efficiently load into exosomes upon co-incubation, without altering vesicle size distribution or integrity. Exosomes loaded with hsiRNAs targeting Huntingtin mRNA were efficiently internalized by mouse primary cortical neurons and promoted dose-dependent silencing of Huntingtin mRNA and protein. Unilateral infusion of hsiRNA-loaded exosomes, but not hsiRNAs alone, into mouse striatum resulted in bilateral oligonucleotide distribution and statistically significant bilateral silencing of up to 35% of Huntingtin mRNA. The broad distribution and efficacy of hsiRNA-loaded exosomes delivered to brain is expected to advance the development of therapies for the treatment of Huntington's disease and other neurodegenerative disorders.

Integrity signals

Registry

Crossref · 10.1038/mt.2016.126

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Administration of hsiRNA-loaded exosomes through unilateral infusion into mouse striatum showed in vivo efficacy, with 35% of HTT mRNA silenced in the brain of mice.

    “Moreover, administration of hsiRNA-loaded exosomes through unilateral infusion into mouse striatum further showed in vivo efficacy of these established exosomes, where 35% of HTT mRNA were silenced in the brain of mice.[106]”
  • Huntington's disease is caused by heightened CAG repeats in the huntingtin (HTT) gene.

    “The cause of HD is related to the heightened CAG repeats in the huntingtin (HTT) gene.[101, 106]”
  • Didiot et al. loaded modified hsiRNAs targeting HTT mRNA into exosomes.

    “In 2016, Didiot et al. efficiently loaded modified small interfering RNA (hsiRNAs targeting HTT mRNA) into exosomes, which are endogenous vesicles applied as siRNA delivery biomaterials.”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Didiot, M.-C., Hall, L. M., Coles, A. H., Haraszti, R. A., Godinho, B. M., Chase, K., Sapp, E., Ly, S., Alterman, J. F., Hassler, M. R., Echeverria, D., Raj, L., Morrissey, D. V., DiFiglia, M., Aronin, N., & Khvorova, A.
Affiliations
  • University of Massachusetts Chan Medical School (US)
  • Massachusetts General Hospital (US)
Corresponding author
Khvorova, Anastasia
Venue
Molecular Therapy
Publisher
Elsevier BV
Published
2016-10
Volume
24
Issue
10
Pages
1836-1847
ISSN
1525-0016 (ISSN-L)
OpenAlex
W2476696777
Cited by
483
References
51
Citations by year
2026: 27 · 2025: 47 · 2024: 65 · 2023: 67 · 2022: 71 · 2021: 68 · 2020: 46 · 2019: 40 · 2018: 30 · 2017: 21 · 2016: 1
FWCI
15.93
Type
journal article
Language
en
Open access
Locations
  • Molecular Therapy (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • eScholarship@UMassChan (submittedVersion, cc-by-nc-nd)
Funders
  • CHDI Foundation
  • National Institutes of Health (UL1TR001453, UH2TR000888, 1s10od020012-01, UL1TR000161, UH3TR000888)
  • National Institute of General Medical Sciences (R01GM108803)
  • National Institute of Neurological Disorders and Stroke (R01NS038194)
  • National Center for Advancing Translational Sciences
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
Keywords
exosomes, siRNA delivery, Huntington's disease, oligonucleotide therapeutics, intracerebroventricular infusion, striatum, cortical neurons, neurodegenerative diseases
MeSH terms
Huntingtin Protein, Animals, Cells, Cultured, Gene Expression Regulation, Humans, Neurons, Genetic Therapy, Gene Silencing, RNA, Small Interfering, Mice, Exosomes, Hydrophobic and Hydrophilic Interactions

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review